Quick Facts

• Condition: Primary biliary cholangitis (PBC)
• Goal: Management of liver conditions; may help delay progression.
• Condition: Cholesterol-rich gallstones
• Goal: May promote the gradual dissolution of certain non-calcified gallstones.

---

Ursobilane (ursodeoxycholic acid) is a therapeutic option used for the management of two primary conditions. Its main use is in the care of patients with primary biliary cholangitis (PBC), a long-term liver condition. In this context, the medication is intended to help manage the disease and may support efforts to improve liver function.

Additionally, Ursobilane is utilized for individuals who have cholesterol-rich gallstones that are radiolucent and non-calcified. For certain patients who face elevated surgical risk, this treatment may be prescribed as an alternative to an operation. The medication is intended to help facilitate the gradual dissolution of these stones over an extended period. It may also be used in an effort to prevent the formation of new gallstones in individuals experiencing rapid weight loss, such as after bariatric procedures. Consult a healthcare provider to determine the appropriate use and management for your specific medical needs.

Regulatory References

1. NIH MedlinePlus guidance

Eligibility Map: Who can and cannot use Ursobilane

The eligibility for Ursobilane (ursodeoxycholic acid) is strictly governed by official regulatory documents, which define specific inclusion and exclusion criteria based on patient condition and population group.

---

Populations for whom use is contraindicated:

• Patients with complete obstruction of the extrahepatic biliary tract, acute inflammation of the gallbladder, or decompensated hepatic cirrhosis.
• Individuals with calcified or radio-opaque gallstones, as the medicine will not dissolve them.
• Patients with known hypersensitivity to UDCA or any component of the formulation.

---

Age-Related Eligibility Rules:

Age Group	Regulatory Status
Adults (General Use)	Approved for Primary Biliary Cholangitis (PBC) and certain cholesterol gallstones.
Children under 6 years	Safety and effectiveness are not established by US and Canadian authorities.

---

Pregnancy and Lactation Eligibility Status:

• Pregnancy: Use is restricted and generally not recommended unless considered clearly necessary. The absence of pregnancy must be confirmed before starting treatment for gallstone dissolution.
• Lactation: Caution is advised as it is unknown if clinically significant amounts are excreted in human milk. Women of childbearing potential should use effective non-hormonal contraception during gallstone treatment.

Ursobilane Interactions with other medicines and products

Ursobilane (ursodeoxycholic acid) exhibits officially documented interactions categorized by effects on absorption, metabolism, and therapeutic action. Interacting substances include:

Substance Class	Interacting Medicines (Examples)	Official Outcome	Procedural Rule
Absorption Inhibitors	Cholestyramine, Aluminum-based Antacids, Colestipol	Reduce Ursobilane absorption and efficacy.	Must be taken at least 2 hours before or after Ursobilane.
Bile Composition Modifiers	Estrogens, Oral Contraceptives, Clofibrate	May counteract the effectiveness of Ursobilane in gallstone dissolution.	Non-hormonal contraception may be necessary for patients with this indication.

Interactions Affecting Exposure of Co-administered Drugs:

• Ciclosporin: Ursobilane can increase the intestinal absorption of Ciclosporin. Regulatory documents require monitoring of Ciclosporin blood concentrations, with dosage adjustments if necessary.
• Nitrendipine/Dapsone: Ursobilane has been shown to reduce the plasma peak concentrations ( C max) and Area Under the Curve (AUC) of Nitrendipine and to reduce the therapeutic effect of Dapsone. These findings suggest a potential for Ursobilane to induce CYP3A enzymes.

These official interaction statements from regulatory documents (e.g., FDA, EMA) govern the appropriate co-administration of Ursobilane with other medicines, focusing on minimizing therapeutic antagonism and managing potential changes in drug exposure.

Ursobilane, which is ursodeoxycholic acid (UDCA), is an epimer of chenodeoxycholic acid and a hydrophilic bile acid that becomes a major fraction of the bile acid pool upon administration. Its primary pharmacodynamic actions are observed in the hepatobiliary system and the gastrointestinal tract.

Mechanistically, UDCA modulates the composition of biliary lipids through multiple pathways. It acts as an inhibitor of intestinal cholesterol absorption at the enterocyte level. Concurrently, it reduces the secretion of cholesterol from the hepatocyte into the bile canaliculi, leading to a decrease in the overall saturation of biliary cholesterol.

At the cellular level, UDCA is a cytoprotectant, accumulating in the membranes of hepatocytes and cholangiocytes. This interaction stabilizes the cell membranes and mitochondria, and promotes the expression of membrane transport proteins, such as the chloride-bicarbonate anion exchanger (AE2), increasing the overall efflux of bile and water into the canaliculi (choleretic action). Intracellularly, it functions as an anti-apoptotic agent by disrupting the mitochondrial pathway of cell death, which involves stabilizing the mitochondrial membrane potential and inhibiting the release of pro-apoptotic factors like cytochrome c. Furthermore, UDCA competitively displaces more toxic, hydrophobic endogenous bile acids from the circulation and bile acid pool, altering the hydrophobicity index of the total bile acid mixture.

How Ursobilane is Used

Ursobilane (ursodeoxycholic acid) is administered exclusively via the oral route as tablets, capsules, or an oral suspension. The dosage regimen is defined by weight-based calculations and varies by the condition being addressed. For the management of Primary Biliary Cholangitis (PBC), the standard daily regimen is calculated to be between 13 and 15 mg per kilogram of body weight. This total daily amount is typically divided and administered in two to four separate administrations, and it is taken with food to ensure consistent intake.

Use for gallstone dissolution involves a lower daily dosage, usually ranging from 8 to 12 mg/kg/day. The administration for this indication is often scheduled so that one of the required doses is taken in the evening or before bedtime. Treatment duration is dependent on the indication: the medicine is part of a long-term therapy for PBC, but gallstone dissolution requires a defined course, typically lasting up to two years, with the standard practice of continuing for an additional three to four months after radiological confirmation of gallstone disappearance.

Administration instructions specify that scored tablets may be broken to adjust the dose, but the segments must be swallowed whole and unchewed. If a dose is missed, the standard procedure is to avoid taking a double dose; the missed dose is either taken immediately or skipped to follow the original schedule. Specific regimens are also utilized for certain populations, such as pediatric patients with cystic fibrosis-associated hepatobiliary disorder, who may require a higher daily dose of up to 30 mg/kg/day in divided administrations.

Research Evidence / Overview of Studies for Ursobilane

---

Evidence for Use in Primary Biliary Cholangitis (PBC)

Research on Ursobilane for Primary Biliary Cholangitis (PBC) was studied in Randomized Controlled Trials (RCTs) and long-term observational cohort studies primarily involving adults. These studies were designed to examine endpoints related to transplant-free survival and changes in biochemical markers like Alkaline Phosphatase (ALP) and Bilirubin. Multiple trials and analyses reported patterns related to measured changes in these markers. Furthermore, long-term data gathered from observational settings included populations where delayed disease progression was observed. However, findings were mixed regarding changes in certain patient-reported outcomes describing perceived discomfort, such as fatigue and itching.

---

Evidence for Use in Cholesterol Gallstone Dissolution

Research has explored the role of the medicine in dissolving radiolucent, cholesterol-rich gallstones using RCTs and prospective studies. These trials were evaluated in a highly selected patient group, typically adults with non-calcified stones. The main outcome researchers monitored was the rate of complete gallstone dissolution. The findings describe patterns observed in these studies where achieving dissolution was reported as a slow process, often requiring extended time. Research also indicates that the reported outcomes may be variable, and success was associated with smaller, non-calcified stones.

---

What is Still Uncertain About Ursobilane's Research Record

A primary research limitation is the limited information available for long-term outcomes across all patient subsets. Specifically, the correlation between short-term changes in biochemical markers observed in PBC trials and the very long-term survival outcomes remains an area where certainty remains low. For gallstone treatment, the evidence highlights that results apply only to the highly selected populations studied. These research limitations mean that findings describe group patterns, and the study results reflect the specific conditions under which they were conducted.

Key Studies & References Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy (Meta-analysis covering gallstone dissolution trials)

Common questions about Ursobilane (FAQ)

Q: Is Ursobilane a steroid or a natural substance?

The active ingredient in Ursobilane, ursodeoxycholic acid, is a naturally-occurring substance in the body. It is a secondary bile acid that is chemically described as a sterol lipid, meaning it is related to the steroid family of compounds. Official regulatory classification identifies it as a Bile Acid Preparation.

Q: How quickly does Ursobilane start working for the intended purpose?

Studies and official information indicate that the time it takes for effects to be observed can vary significantly depending on the condition being addressed. The medicine is generally described as a long-term therapy for conditions like Primary Biliary Cholangitis (PBC), and for dissolving gallstones, official documents report that the process is typically slow and requires an extended treatment time.

Q: Is it normal to feel more tired when starting Ursobilane?

According to official regulatory safety summaries, fatigue (tiredness) is an adverse reaction that has been reported as common, meaning it affects between 1% and 10% of patients. Concerns about persistent fatigue can be discussed with a healthcare provider.

Q: Can men and women use Ursobilane for the same conditions?

The indications for use, such as Primary Biliary Cholangitis and the dissolution of certain gallstones, are applicable to both adult men and non-pregnant adult women. The official prescribing information for these approved uses does not define specific restrictions based on the patient’s sex.

Q: What are the signs of a serious side effect from Ursobilane?

Serious reactions that have been documented as very rare include the potential for decompensation (worsening) of liver cirrhosis in patients with advanced disease. Other documented reactions include severe pain in the upper right part of the abdomen. These signs, though very rare, are noted in regulatory safety documents.

Q: Do official documents mention any effects of Ursobilane on fertility?

Non-clinical studies, which examine the effects of the medicine on reproductive performance in animals, reported no treatment-related effects on fertility. This information is contained within the official regulatory labeling.

Q: Why do official materials sometimes mention 'fat-soluble vitamins' in relation to this drug?

Official documents note the medicine's effect on bile composition, which can indirectly influence the body's ability to absorb other substances, including fat-soluble vitamins. The potential effect on absorption may require evaluation as part of patient care.

Q: Can older adults use Ursobilane?

Use is generally approved for adults across a wide age range. According to official product information, specific dose adjustments are not typically provided solely based on advanced age unless an individual has other conditions, such as impaired liver or kidney function.

Q: What does 'contraindication' mean in relation to Ursobilane?

A contraindication is an official regulatory warning that states a specific condition or factor that absolutely prevents the use of the medical treatment due to the high risk of harm. For Ursobilane, examples include having calcified gallstones or acute inflammation of the gallbladder.

Q: Does Ursobilane contain any ingredients that could trigger gluten sensitivity?

Medications are not required to follow the same gluten-free labeling rules as food products in the US. However, official regulatory labels do list all the inactive ingredients (excipients). The inactive ingredients are listed for reference and are available for review with a healthcare professional.

Q: What are the general expectations for a follow-up appointment while on Ursobilane?

Regulatory documents advise that for patients being treated for Primary Biliary Cholangitis, liver function parameters (such as AST, ALT, and gamma-GT) should be monitored. This is typically done by a physician every four weeks for the first three months of treatment, and then every three months thereafter.

Q: Can Ursobilane cause changes in mood or sleep?

Yes, official regulatory safety summaries list insomnia (trouble sleeping) as a common adverse reaction, which is a psychiatric effect, occurring in up to 10% of patients. This information is included in the medicine’s official product information.

Q: Does Ursobilane affect the results of common blood tests?

The treatment is associated with monitored changes in certain liver health markers (e.g., AST, ALT, and gamma-GT). Regulatory documents advise that these tests should be monitored regularly because the drug may influence these specific laboratory values.

Q: What are the long-term effects described in regulatory summaries?

Long-term observational studies for primary biliary cholangitis have reported patterns associated with delayed disease progression in some groups. However, official research summaries also note a limited amount of information available on very long-term outcomes across all patient groups.

Q: Is Ursobilane available as a generic medicine?

The active ingredient is ursodeoxycholic acid, which is the recognized generic name for the substance. This generic name is widely used in medicine.

Q: Can Ursobilane cause changes to the skin or hair?

Official regulatory safety summaries list alopecia (hair loss) and skin rash as common adverse reactions. Urticaria (hives) is listed as a very rare reaction in the same official product information.

Q: Why do official documents state that Ursobilane should be used with caution in some groups?

Official documents advise caution because certain pre-existing conditions, such as the presence of calcified gallstones or advanced decompensated liver cirrhosis, are associated with a risk of the medicine worsening the existing disease. Caution is therefore necessary to mitigate these risks.

Q: What does 'evidence indicates' regarding the effectiveness of Ursobilane for its primary uses?

Evidence indicates the medicine is associated with measured changes in certain biochemical markers in patients with Primary Biliary Cholangitis. For gallstone dissolution, studies report success in highly selected populations with smaller, non-calcified stones.

Q: Why are routine blood tests sometimes needed while taking Ursobilane?

Routine blood tests are advised to monitor liver function parameters (such as AST, ALT, and gamma-GT). This monitoring is required by regulatory documents to enable early detection of potential changes in liver health, especially during the initial phase of treatment.

How to Store and Dispose of Ursobilane?

The storage and disposal of Ursobilane (ursodeoxycholic acid) must adhere strictly to the conditions specified in regulatory labeling to maintain stability and ensure safety.

---

Storage Conditions

• Temperature: Store the medicine at a temperature not exceeding 25 C.
• Protection: The product must be kept in its original container to ensure protection from light and maintain integrity.
• Safety: Like all medicines, Ursobilane must be stored out of the sight and reach of children.

---

Disposal Instructions

• Unused Product: Any unused or expired Ursobilane and waste material must be disposed of in accordance with local requirements.
• Environmental: Do not discard this medicine via household waste or wastewater; consult a pharmacist or local authority for proper pharmaceutical disposal.